Drugs / [18F]APN-1607
[18F]APN-1607
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05043675 | Sep 2021 → Sep 2024 | Alzheimer disease | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT03545789 | Mar 2018 → Feb 2020 | Alzheimer disease, progressive supranuclear palsy | Invicro | Completed | No outcome recorded |
| Phase 1 | NCT03472313 | Nov 2017 → Apr 2018 | — | Invicro | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04141150 | Mar 2022 → Sep 2024 | Alzheimer disease | APRINOIA Therapeutics, LLC | Unknown | No outcome recorded |
| Phase 2 | NCT04305210 | Dec 2019 → Jan 2021 | Alzheimer disease | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04169126 | Apr 2019 → Mar 2023 | Alzheimer disease | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07422857 | Jan → Dec 2026 expected | Alzheimer disease | JYAMS PET Research & Development Limited | Recruiting | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]APN-1607 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04141150 ↗ |
| Known as | 18F-PM-PBB3 | “Recently a second-generation tau PET image tracer 18F-PM-PBB3 (APN-1607 or MNI-958) has been developed by National Institute of Radiological Sciences.” NCT04169126 ↗1“Recently a new tracer 18F-PM-PBB3 has been introduced in tau PET images.” NCT04305210 ↗ |
| Known as | [18F]MNI-958 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03472313 ↗ |
| Known as | APN-0000455 | “The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-958 also known as APN-0000455 or PM-PBB3, as a tau targeted radiopharmaceutical.” NCT03472313 ↗ |
| Known as | APN-1607 | “Recently a second-generation tau PET image tracer 18F-PM-PBB3 (APN-1607 or MNI-958) has been developed by National Institute of Radiological Sciences.” NCT04169126 ↗ |
| Known as | F-18 PMPBB3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04305210 ↗ |
| Known as | MNI-958 | “Recently a second-generation tau PET image tracer 18F-PM-PBB3 (APN-1607 or MNI-958) has been developed by National Institute of Radiological Sciences.” NCT04169126 ↗ |
| Known as | PM-PBB3 | “The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-958 also known as APN-0000455 or PM-PBB3, as a tau targeted radiopharmaceutical.” NCT03472313 ↗ |
| Modality | Diagnostic / imaging agent | “as a tau targeted radiopharmaceutical.” NCT03472313 ↗ |
| Route | Other | “single \[18F\]MNI-958 injection” NCT03472313 ↗ |